Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab tirumotecan + envafolimab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Sacituzumab tirumotecan + envafolimab is an investigational combination therapy consisting of a TROP2-directed antibody-drug conjugate (ADC) and a PD-L1-directed immune checkpoint inhibitor. Sacituzumab tirumotecan (also known as MK-2870 or SKB264) comprises a humanized anti-TROP2 monoclonal antibody conjugated to a belotecan-derived topoisomerase I inhibitor payload (KL610023) via a proprietary sulfonyl pyrimidine-thiol linker, with a drug-to-antibody ratio (DAR) of approximately 7.4. Envafolimab is a recombinant humanized single-domain antibody (nanobody) that targets PD-L1. This combination is being evaluated in Phase II clinical trials for the treatment of patients with TROP2-positive advanced biliary tract cancers who have progressed on prior immunochemotherapy, aiming to leverage the cytotoxic effects of the ADC alongside the immune-potentiating effects of PD-L1 blockade.
- Other names
- sacituzumab tirumotecan combined with envafolimab
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on sacituzumab tirumotecan + envafolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab tirumotecan + envafolimab.